Obstructive sleep apnea (OSA) is a highly prevalent disorder characterized by recurrent upper airway obstruction during sleep. These episodes are terminated by arousals and are commonly associated with hypoxemia. The acute hemodynamic and autonomic perturbations that accompany obstructive apneas can lead to sustained diurnal hypertension. [1] [2] [3] In a cross-sectional study of a sleep clinic patients 60% of men and women with severe OSA had hypertension. 4 In populationbased prospective studies, patients with severe OSA had three times the risk of developing hypertension within 5 years, independent of other risk factors. 1 Current evidence suggests that sympathoexcitation, inflammatory processes, oxidative stress, and endothelial dysfunction play important roles in the pathogenesis of hypertension and vascular complications in OSA. [5] [6] [7] [8] [9] However, the exact mechanisms of hypertension and varying susceptibility to endothelial dysfunction among patients with OSA are not well understood.
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Endothelial-dependent vasodilatory capacity is primarily regulated by local production of nitric oxide (NO) and modulated by carbon monoxide (CO). [10] [11] [12] CO is predominantly released during heme metabolism by heme oxygenase (HO), generating iron and biliverdin. Biliverdin is further metabolized to bilirubin by biliverdin reductase. HO has been reported to be present in all tissues and colocalizes with NO synthase in the vasculature. 13, 14 Like NO, the ability of CO to relax blood vessels occurs through soluble guanylate cyclase with increases in guanosine 3′,5′-cyclic monophosphate (cGMP) and activation of calcium-gated potassium channels. 15, 16 The activation of potassium channels inhibits calcium entry from voltage-activated calcium channels resulting in vasodilatation. 17 While the majority of data supports a positive modulatory role of CO, evidence for existence of vasoconstrictor effect of CO has also accumulated. CO has been demonstrated to have dual vasoregulatory function depending on the local NO concentrations. 18, 19 The positive modulatory effect of CO on soluble guanylate cyclase is present only when the tissue level of NO is low. 20 However, under conditions when NO is abundant such as in resistance arterioles, 21, 22 notwithstanding the higher affinity of NO for soluble guanylate cyclase, CO targets soluble guanylate cyclase and down modulates NO-mediated vasodilatation. [18] [19] [20] [23] [24] [25] This concept is further supported by the observation that increased CO via site-specific overexpression of HO in vascular smooth muscle cells by threefold attenuates cGMP production in response to NO, impairs NO-mediated vasodilatation, and causes hypertension. 18 These transgenic mice exhibit a significant increase in arterial pressure and display impaired vasodilatory responses to NO in isolated aortic segments while enhancing their NO production compared with their nontransgenic littermates. 18 Conversely, inhibition of HO by tin protoporphyrin restores cGMP levels and blood pressure. 18 Further, the role of CO in attenuating vasodilatation in response to NO is demonstrated in bovine pulmonary artery where induction of HO with two to fourfold increase in its activity by either cobalt chloride or Co-protoporphyrin IX resulted in decreased cGMP production and attenuation of pulmonary artery relaxation to the NO-donor spermine-NONOate. 25 Moreover, excess endogenous CO, even at low levels, can reflect underlying inflammatory and oxidative stress in critical illness 26 and vascular pathology. 27 HO expression is increased in patients with OSA 28 with elevated endogenous blood levels of CO. 29 The role of CO in vascular function and its relationship to hypertension in patients with OSA is unknown. We sought to investigate the roles of HO and NO in endothelial function and hypertension in patients with OSA. These findings were compared and contrasted with a group of non-OSA patients with and without hypertension to specifically examine the roles of OSA itself and HO in endothelial dysfunction.
Methods

Subjects.
Patients with newly diagnosed and untreated moderate to severe OSA (apnea-hypopnea index (AHI) ≥20 events/h) and those without OSA or other sleep disorders (AHI <5 events/h) as comparison group were sequentially recruited from the Yale Center for Sleep Medicine. We specifically recruited patients with moderate to severe OSA for two reasons: (i) this population is particularly at increased risk of hypertension and (ii) for proof-of-concept for the role of CO in vascular dysfunction. Hypertension was defined by blood pressure ≥140 mm Hg systolic blood pressure or ≥90 mm Hg diastolic blood pressure, which had been previously documented by using appropriate sized cuff and measurements that had been made at least in three different occasions according to the standard criteria. 30 Subjects were excluded if they had known peripheral vascular disease, liver disease, hemolytic anemia, inflammatory disease, active infection, or if they were pregnant, on therapy for OSA, on chronic steroid treatment, or younger than 18 years of age. Each subject was informed of the experimental procedures and signed the consent form approved by the Human Investigation Committee of the Yale University School of Medicine, study protocol (no. 12719).
Sleep study. Nocturnal polysomnography was performed as previously described. 31 Respiratory events were scored according to the American Academy of Sleep Medicine. Hypopnea was scored when there was at least 30% decrease in airflow signal with a ≥4% decrease in oxygen saturation. 32 Endothelial function. Conduit vessels respond to alterations in blood flow by increasing vessel diameter via an endothelialdependent mechanism. Endothelial function was assessed by a standard flow-mediated vasodilatation (FMD) method using Doppler ultrasound of the brachial artery. 33 The artery diameters were measured independently by the two investigators (one blinded to grouping) using a digital caliper and were verified by an automated border recognition software. Peak vasodilatation was calculated as the percent change in the brachial artery diameter from baseline to peak reactive hyperemia. The inter-and intra-observer variability in diameter measurements was <5%.
Blood sample. Venous blood sample was obtained after FMD measurement from opposite arm. The subjects had been seated and rested for 30 min. Plasma and serum were separated with centrifugation at 1,200g for 10 min at 4 °C, aliquoted and stored at −80 °C for further analysis.
HO activity. HO activity was determined indirectly by elaboration of its end products, CO and bilirubin. The bulk of heme is oxidized by HO to CO, which is formed in equimolar amounts to biliverdin. Biliverdin is further metabolized to bilirubin by biliverdin reductase which is not a rate-limiting enzyme. However, there are minor HO-independent sources of CO, which include oxidation of organic molecules and peroxidation of membrane lipids. 34 Exhaled CO. In the absence of acute or chronic pulmonary disease, or smoking, exhaled CO accurately reflects an individual's total blood CO, which largely reflects the activity of pathways involved in endogenous CO cycling. 35, 36 Exhaled CO was measured with a calibrated fuel cell type electrochemical device with sensor sensitivity of 1 ppm (parts per million) (Bedfont Scientific, Kent, UK). The mean of three reproducible measurements was recorded and corrected for ambient CO.
Bilirubin assay. Measurements of total bilirubin were performed with a QuantiChrom Bilirubin Assay Kit (DIBR-180; BioAssay System, Hayward, CA) using colorimetric assay (Jendrassik-Grof method) according to the manufacturer's instructions. Serum bilirubin concentrations were expressed as mg/dl. Detection limit was 0.16 mg/dl bilirubin.
NO assay. The plasma levels of NO metabolites, nitrite and nitrate, were measured according to Griess reaction (R&D Systems, Minneapolis, MN).
cGMP assay. Guanylate cyclases are either soluble or membrane bound. Vascular smooth muscle relaxation occurs due to increases in cGMP through activation of soluble guanylate cyclase in response to NO and CO. 16, 17 Serum levels of cGMP were measured quantitatively using ELISA kit (Abnova, Walnut, CA). The inter-and intra-assay coefficients of variation were 6%.
Data analysis. The primary outcome was FMD. HO end products, NO metabolites, and cGMP were secondary outcomes. The pre-planned comparisons were between the non-OSA pair (normotensive vs. hypertensive) and between the OSA pair (normotensive vs. hypertensive) as well as between OSA and non-OSA counterparts to examine the effect of OSA itself. We specifically included the comparison groups from the clinic population to closely match for attributes other than the two phenotypes of interest, OSA and hypertension. The required sample size to detect a significant change in FMD (δ = 4, s.d. = 2.7) was 14 per group (α = 0.05, power = 80%). However, we oversampled the OSA groups to account for the differential vulnerability and responses to OSA and hypoxia. Data are expressed as mean ± s.e. Data were analyzed using analysis of variance for simultaneous comparisons of the groups (Graphpad Prism, La Jolla, CA). Spearman correlation was used to analyze the relationship between FMD and NO and CO. A multivariable linear regression analysis was used to identify independent variables associated with FMD. The following variables were considered for inclusion in the comprehensive model: age, sex, body mass index (BMI), smoking, diabetes, dyslipidemia, statin use, hypertension, and OSA. Inclusion in the final model was determined by a backward-stepwise technique evaluating all potential univariate variables (P < 0.20) to create a multivariable model containing variables with P < 0.05 (SAS Institute, Cary, NC). To further address the potential role of age particularly in the hypertensive OSA group, we performed a subgroup analysis for the ages below and above 55 years for the outcomes in patients with both hypertension and OSA. P values were twosided with a level of significance of P < 0.05. 
subjects' characteristics
There were 63 subjects with OSA and 33 subjects in the comparison group without OSA. The comparison groups had snoring with no OSA, oxygen desaturation or any other comorbid sleep disorders. One subject in group 2 had to be excluded because of insufficient data and suboptimal FMD study. The subjects' median age was 50.0 years with interquartile range of 15.8. Patients with OSA and hypertension (group 4) were older by 8 years compared to normotensive OSA (group 3). The median BMI for the entire cohort was 33.7 kg/m 2 with interquartile range of 15.8 ( Table 1) . The univariable analysis including age, sex, BMI, smoking, diabetes, dyslipidemia, statin use, hypertension, and OSA showed age, diabetes, hypertension, and OSA to have significant regression coefficients with FMD as the outcome ( Table 2) . Adjusting for these variables in a multivariable model resulted in the loss of influence of age and diabetes with retention of hypertension and OSA as significant predictors of impaired FMD. OSA subjects with and without hypertension had similar sleep apnea severity and hypoxia exposure during sleep and were comparable in terms of BMI, AHI, sleep time with arterial oxygen saturation <90%, and oxygen desaturation index. The OSA group had severe OSA with AHI of 41 ± 5/h in the normotensive group and AHI of 48 ± 4/h in the hypertensive subjects (P = not significant). The oxygen desaturation indexes were 32 ± 5 and 36 ± 4/h, respectively.
FMd
FMD was significantly lower in hypertensive OSA compared to hypertensive non-OSA, 8.0 ± 0.5% vs. 10.5 ± 0.8%, P < 0.01, (Figure 1) . Likewise, normotensive OSA subjects had lower FMD (13.5 ± 0.5%) than those without hypertension and OSA (16.1 ± 1.0%) suggesting that OSA impairs FMD without necessarily being associated with hypertension. Similarly, hypertension alone without OSA is associated with impaired FMD. Multivariable linear regression analyses were performed to identify which variables were independently associated with FMD. The final model showed that variables correlating with FMD were OSA (parameter estimate = −2.69, P = 0.004) and hypertension (parameter estimate = −5.37, P < 0.0001). Age, other comorbidities, and medications did not have a significant effect on FMD in the model. To further address the potential role of age particularly in the hypertensive OSA group, we performed a subgroup analysis for the ages below and above 55 years for the outcomes. There were no differences in FMD, CO, NO, and GMP levels between the two subgroups. There was a significant statistical correlation between AHI and FMD but with only a modest correlation coefficient (r = 0.31, P = 0.003, data not shown) showing that the higher the AHI the lower the FMD. Less than 10% of the variance in FMD could be attributed to AHI. No correlation was found between FMD and sleep time with arterial oxygen saturation <90% and oxygen desaturation index. This is likely due to the study design where groups 3 and 4 where comparable in terms of OSA severity and oxygen desaturation indexes.
exhaled co
Hypertensive OSA subjects had significantly higher levels of exhaled CO (3.35 ± 0.26 ppm) than normotensive OSA subjects (2.40 ± 0.18 ppm), P = 0.01. Likewise, in the non-OSA group the hypertensive patients had higher levels of exhaled CO compared with the normotensive counterparts (3.46 ± 0.56 ppm vs. 2.29 ± 0.27, P = 0.02, respectively). The levels of exhaled CO were elevated and comparable in OSA and non-OSA hypertensives (Figure 2) .
serum total bilirubin
Serum bilirubin concentrations were significantly increased in only hypertensive OSA subjects compared with normotensive OSA or non-OSA hypertensives (Figure 2) . Thus, the elevated concentrations of both CO and bilirubin in subjects with OSA and hypertension indicate activation of HO rather than as the result of non-HO pathways.
correlations Between FMd, exhaled co, and bilirubin
There was a significant inverse relationship between both exhaled CO and bilirubin and FMD showing the higher the exhaled CO or bilirubin the lower the vasodilatory capacity (Figure 3) .
no
Total serum NO metabolites were significantly higher in hypertensive OSA (28.1 ± 2.8 μmol/l) compared with normotensive OSA (17.9 ± 1.4 μmol/l), P = 0.003. More importantly, there was a marked difference in NO levels between Data are means ± s.e. ACI, angiotensin-converting inhibitors/receptor antagonists; AHI, apnea-hypopnea index; BMI, body mass index; DBP, diastolic blood pressure; ODI, oxygen desaturation index; OSA, obstructive sleep apnea; SaO 2 , arterial oxygen saturation; SBP, systolic blood pressure. a P value significant between groups 3 and 4; b P value significant between groups 1, 2, and 4; c P value significant between groups 1, 2, and 3.
hypertensive OSA (28.1 ± 2.8 μmol/l) and hypertensive non-OSA subjects (19.4 ± 2.8 μmol/l), P = 0.032, indicating a mechanism of increased NO unique to OSA with hypertension ( Figure 4) .
cgMP
Serum cGMP levels were significantly lower in hypertensive OSA (12.9 ± 1.8 pmol/ml) compared with normotensive OSA (20.6 ± 3.7 pmol/ml), P = 0.032. There was no difference in serum cGMP levels amongst groups 1, 2, and 3. In addition, there was no difference in cGMP concentrations between groups 3 and 4 ( Figure 2 ). This lack of statistical difference in cGMP between hypertensive OSA and non-OSA could be as a result of a type II error because sample size was calculated for the primary outcome of FMD. However, it can be argued that since there is no difference in cGMP levels between normotensive and hypertensive non-OSA, then cGMP may not be playing a role in hypertension in the latter group. On the contrary, since there is a difference in cGMP concentrations between normotensive and hypertensive OSA, then it is possible that lower cGMP may be contributing to lower vasodilatory capacity and hypertension in the latter group.
discussion
We studied the roles of CO and NO in endothelial function and their clinical significance in hypertension in OSA. To the best of our knowledge, this is the first report in humans that shows increased HO expression may be associated with endothelial dysfunction and hypertension in patients with OSA. This vascular dysfunction was associated with suppressed activity of soluble guanylate cyclase and decreased cGMP concentrations. Perturbation in endothelial-dependent vasodilatory capacity in hypertensive OSA subjects was in the setting of elevated CO and NO levels. Hypertensive subjects without OSA also had impaired vasodilatory capacity but it was less pronounced than those with OSA. This is consistent with the studies that have shown the additive effects of OSA and hypertension on arterial stiffness. 37, 38 In the hypertensives without OSA, NO was not elevated and CO appeared to be from non-HO sources because of unchanged bilirubin concentrations. The non-HO sources of CO, which may emanate from cells other than endothelial cells, may not have the same temporal or spatial relationship with NO. Therefore, it is possible that elevated CO concentrations in hypertensive non-OSA may not have the same physiologic effects as in those with OSA. The key point in our findings is the elevated concentrations of NO in hypertensive OSA compared with normotensive OSA and hypertensive non-OSA. As discussed in the introduction, CO may exert an inhibitory effect on guanylate cyclase lowering cGMP depending on the redox state of the cells and NO concentrations. [18] [19] [20] [21] [22] [23] [24] [25] It is not known why the hypertensive OSA, in particular, had increased concentrations of NO. There are potential mechanisms that can explain this finding. One possibility is that increased NO is due to upregulation of endothelial NO synthase by low cGMP 18 or by excess production of H 2 O 2 . 39 There is also evidence that CO can displace and release NO from hemoproteins and intracellular thiols. [40] [41] [42] Our data on NO are in contrast to previous Flow-mediated vasodilatation as a measure of endothelial-dependent vasodilatory capacity is markedly impaired in patients with both Osa and hypertension (HtN) (n = 36) compared with hypertensive non-Osa (n = 13, P < 0.01) and normotensive Osa (n = 27, P < 0.0001). In addition, there was significant difference in vasodilatory capacity between normotensive non-Osa (n = 19) and normotensive Osa (n = 27, P < 0.008) indicating impairment independent of presence of HtN in Osa. Osa, obstructive sleep apnea. reports that have shown decreased plasma concentrations of NO metabolites in OSA. 43, 44 It should be noted that reports on the levels of NO in OSA in the literature are far from being consistent. Measurements of exhaled NO or plasma nitrotyrosine in OSA showed no significant differences from the controls. 45, 46 Further, in another study there was no significant change in NO metabolites in patients with OSA after treatment with positive airway pressure. 47 Our results on NO are in accord with those of Gjorup et al. that showed increased NO synthesis and release in patients with OSA. 48 Our data are consistent with the in vitro studies and transgenic models showing dual role of CO in vasoregulation. 12, 18, 19, 24 Further support for the role of HO and specifically CO in hypertension and OSA comes from clinical studies that show the treatment of OSA with nocturnal continuous positive airway pressure reduces bilirubin and CO levels in blood, 29, 49 improves endothelial function, 6, 8, 9 and ameliorates hypertension. [50] [51] [52] A recent Framingham study concluded that exhaled CO concentration predicts the development of future cardiovascular events with an odds ratio of 1.66 (95% confidence interval 1.14-2.40, P = 0.008) in a multivariable analyses that included adjustment for smoking status. 53 Further, the presence of metabolic syndrome, a constellation of obesity, diabetes mellitus, and dyslipidemia, as covariates, did not significantly alter the relationship of exhaled CO to cardiovascular disease risk after adjusting for traditional risk factors (hazard ratio, 1.64; 95% confidence interval 1.41-1.90; P < 0.0001).
There are some limitations in the study. The groups are not fully matched for age, BMI, comorbidities, and medications. However, multivariable analyses did not show significant effects on endothelial function by age, BMI, smoking, comorbidities or medications among the groups. The diagnosis of hypertension was not based on 24-h ambulatory blood pressure monitoring but was on the basis of measurements at least in three different occasions according to standard criteria. The degree of vasodilatation during FMD measurement turned out to be higher than previously reported studies. However, with the use of automated border recognition software, as well as manual measurement with digital caliper of artery diameter changes we eliminated any systematic errors in FMD. No dietary restriction was imposed to eliminate the influence of diet on NO metabolites. However, the consistency of the results in groups 1, 2, and 3 eliminated the possibility of elevated levels of NO in group 4 to be due to the influence of diet. We did not study the effect of airway pressurization on blood pressure and biochemical correlates because it has been shown that CO decreases with treatment but the blood pressure may not decrease due to arterial wall remodeling. In view of the nature of the study, we are reporting an association between HO end products and endothelial dysfunction and hypertension in OSA. No definitive conclusion about the causal link can be drawn from this study.
In conclusion, we have shown that patients with OSA that exhibit systemic arterial hypertension have increased HO activity with elevated CO and bilirubin concentrations, decreased cGMP levels, and markedly impaired vasodilatory capacity. In the subpopulation of patients with OSA and hypertension, CO may conceivably play a role in the pathogenesis of hypertension. The mechanism of activation of HO in this group is not clear so as individual vulnerability to development of hypertension. The disparate biological and vascular responses to hypoxemia and arousals among patients with OSA deserve further research for better understanding of the cardiovascular disease risk and management in this population. In addition, our findings provide potential avenues to explore the pathophysiological roles of CO and NO in cardiovascular diseases in general and hypertension in particular.
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